C+78/100
Graded #8Editorial review
Ro
A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.
Visit Ro ↗Editorial review — no commercial relationship.
- Semaglutide
- Not disclosed
- Tirzepatide
- Not disclosed
- Coverage
- Multi-state
- Brand-name
- Yes
Factor breakdown
Each of the six graded dimensions. See the methodology.
Cost value68/100
Dose & formulation86/100
Clinical oversight86/100
Labs & monitoring82/100
Fulfillment84/100
Contract terms80/100
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Bottom line — Grade C+
Best for: Patients who want brand-name capability and insurance navigation.
Pricing/verification reflect Ro's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.